tiprankstipranks
Arix Bioscience PLC (GB:ARIX)
LSE:ARIX

Arix Bioscience (ARIX) Income Statement

0 Followers

Arix Bioscience Income Statement

Last quarter (Q2 2022), Arix Bioscience's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, Arix Bioscience's net income was £―. See Arix Bioscience’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
-£ 112.00K£ 340.00K£ 477.00K£ 506.00K£ 1.33M
Cost of Revenue
------
Gross Profit
-£ 112.00K----
Operating Expense
-£ 5.41M£ 4.80M£ 7.79M£ 12.50M£ 15.03M
Operating Income
-£ -5.29M£ -4.46M£ -7.31M£ -11.99M£ -13.70M
Net Non Operating Interest Income Expense
-£ 1.58M£ -156.00K£ 101.00K£ 769.00K£ 708.00K
Other Income Expense
-£ 30.77M----
Pretax Income
-£ -27.58M£ -61.08M£ 126.30M£ -75.57M£ 42.76M
Tax Provision
-£ -4.00K-£ 0.00£ -5.88M£ 5.88M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ -27.57M£ -61.08M£ 126.30M£ -69.69M£ 36.88M
Basic EPS
-£ -0.22£ -0.48£ 0.97£ -0.54£ 0.31
Diluted EPS
-£ -0.21£ -0.48£ 0.89£ -0.54£ 0.29
Basic Average Shares
-£ 124.10M£ 126.95M£ 130.50M£ 129.95M£ 118.79M
Diluted Average Shares
-£ 132.36M£ 136.43M£ 142.34M£ 129.95M£ 128.52M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
-----£ 642.00K
Total Expenses
-£ 5.41M£ -4.80M£ 7.79M£ 12.50M£ 15.03M
Net Income From Continuing And Discontinued Operation
-£ -27.57M£ -61.08M£ 126.30M£ -69.69M£ 36.88M
Normalized Income
-£ -27.58M£ -42.05M£ -8.83M£ -10.95M£ -7.25M
Interest Expense
------
EBIT
-£ -27.58M£ -61.08M£ -7.31M£ -11.99M£ -13.70M
EBITDA
-£ -27.35M£ -61.08M£ -6.98M£ -11.55M£ -13.20M
Currency in GBP

Arix Bioscience Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis